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Familial Dilated Cardiomyopathy: 




Heart failure implies a considerable burden for patients and resources for the 
health care system. Dilated cardiomyopathy is defined as left ventricular dilation 
and reduced systolic function, not solely explained by ischemic heart disease or 
abnormal loading conditions. Numerous genes have been identified in familial cases 
of dilated cardiomyopathy. Heart failure with reduced ejection fraction increases 
the risk for sudden cardiac death. Implantable cardioverter defibrillator therapy 
can provide a means of preventing sudden cardiac death in those deemed to be 
at high risk. Health care providers are in need of better tools in order to improve 
risk stratification. This chapter aims to provide an overview of the current knowl-
edge about risk of arrhythmia and sudden death in patients with familial dilated 
 cardiomyopathy, in particular for those patients with a specific mutation.
Keywords: arrhythmia, cardiology, cardiomyopathy, genetic, heart failure,  
sudden cardiac death
1. Introduction
The prevalence of heart failure is approximately 1–2% in the adult population 
and is 10% for those above the age of 70 years [1]. Dilated cardiomyopathy (DCM) 
is a common form of heart failure defined by dilatation of the left ventricle and 
reduced ejection fraction [2]. In later phases, dilation of the right ventricle and both 
atria is often seen, although this is not required for diagnosis. The disease confers a 
reduction in left ventricular ejection fraction but in early stages dilatation of the left 
ventricle can be seen with only minimal reduction of systolic function. Definitions 
vary, sometimes a distinction is made between ischemic and nonischemic DCM; 
however more often DCM refers to a disease that is not explained by coronary artery 
disease or abnormal loading conditions due to hypertension or valve defects [2]. 
With this definition the prevalence is at the least 1 in 2500 in the general popula-
tion, which is likely an underestimation and some estimates refer the prevalence as 
high as 1 in 250 [3, 4]. In more than 20% of these patients a known disease causative 
mutation is found [3, 5]. Mutations in more than 50 different genes have been 
associated to DCM and some of the most common are the genes encoding for lamin 
A/C, titin, and desmin [1, 6]. Often the phenotype is the similar regardless of the 
causative mutation, therefore broad gene panels are used in genetic testing. Some 






Definitions of cardiomyopathies differ over time and between clinical traditions. 
While in the future cardiomyopathies might be classified after causative mutations, 
they have traditionally been classified by phenotype and cardiac morphology, e.g. 
DCM or hypertrophic cardiomyopathy (HCM). This system of classification has the 
advantage that the phenotype is most often known prior to the genotype.
Originally, cardiomyopathies were considered distinct primary myocardial 
disorders of unknown etiology, whereas heart muscle disorders of known etiol-
ogy or caused by systemic disease were classified as secondary or specific heart 
muscle disease. In 2006 the American Heart Association proposed a classification 
that defined cardiomyopathies either as primary or secondary, referring either to 
a disease were the heart is the sole or primarily affected organ, alternatively where 
myocardial involvement is part of a systemic disease [7]. However, in 2008, the 
European Society of Cardiology (ESC) proposed an alternate classification in which 
a cardiomyopathy is defined as “a myocardial disorder in which the heart muscle is 
structurally and functionally abnormal in the absence of coronary artery disease, 
hypertension, valvular disease and congenital heart disease sufficient to cause the 
observed myocardial abnormality”. Furthermore, the ESC subdivides cardiomy-
opathies depending on morphology and function as well as based upon inheritance 
pattern; distinguishing between familial or genetic forms versus non-familial or 
non-genetic forms of cardiomyopathy (Figure 1) [2].
2.2 Dilated cardiomyopathy
DCM is a distinct cardiomyopathy and a common cause of heart failure defined 
by dilatation of the left ventricle and reduced ejection fraction [2]. In later phases 
dilation of the right ventricle and the atria is often seen, however this is not required 
for diagnosis. For the diagnosis of DCM, the reduction in global systolic function 
should not solely be attributable to coronary artery disease or abnormal loading 
conditions (hypertension, valve disease) [2].
Figure 1. 
Classification of cardiomyopathies proposed by the European Society of Cardiology [2]. Cardiomyopathies 
are primarily classified according to morphology and function, then based on whether the disease is familial 
or non-familial, and lastly depending on either known disease causing mutation or pathophysiological 
mechanism.
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2.3 Familial dilated cardiomyopathy
Familial DCM is diagnosed when at least two relatives (first-degree or second-
degree) meet the diagnostic criteria for DCM [8].
3. Diagnostic evaluation of dilated cardiomyopathy
3.1 Echocardiography
Diagnostic evaluation for suspected heart failure should be managed in accordance 
with guidelines, such as those of the ESC [1]. Echocardiography constitutes a corner-
stone of the evaluation and is readily available. For the diagnosis of DCM both left 
ventricular systolic dysfunction, as well as dilatation of the left ventricle, needs to be 
present and not explained by coronary artery disease or abnormal loading conditions 
(hypertension, valve disease) [9]. Left ventricular systolic dysfunction is defined 
as abnormal left ventricular systolic ejection fraction measured with any modality, 
preferentially echocardiography or cardiac magnet resonance tomography. Left 
ventricular dilatation (Figure 2) is defined as left ventricular end-diastolic volumes 
or diameters >2 standard deviations according to nomograms (Z > 2 standard devia-
tions) after correction for body surface area and age, or body surface area and sex [9].
3.2 Cardiac magnetic resonance tomography
Cardiac magnetic resonance tomography is valuable as a complement to echo-
cardiography. It allows for a better evaluation of the whole myocardium including 
the right ventricle and septum which provides aid in ruling out other cardiomyopa-
thies such as arrhythmogenic right ventricular cardiomyopathy (ARVC) and HCM. 
Myocarditis has been identified as a cause of acquired forms of DCM [10]. Cardiac 
magnetic resonance can be used to assess the presence of active myocarditis as well 
as scar tissue that could indicate previous episodes of myocarditis. Cardiac magnetic 
resonance imaging is, according to the ESC, indicative of active myocarditis if it, in 
the setting of clinically suspected myocarditis, fulfills 2 out of 3 Lake Louise criteria 
[11]. These criteria include; high signaling on T2-weighted images (indicative of 
edema), early gadolinium enhancement (indicative of increased blood flow), and 
late gadolinium enhancement (indicative of scar tissue) [11].
Figure 2. 
Echocardiography with apical four chamber view showing spherical dilatation of the left ventricle. Image adapted 




Of particular importance is a family history of cardiomyopathy, arrhythmia or 
sudden cardiac death. If another family member also fulfills the criteria for DCM 
the patient can be said to have familial DCM [8]. A pedigree, a family tree, could 
be drawn to visualize what family members are affected by the disease or certain 
symptoms as well as how they are related to each other. By doing this the type of 
inheritance pattern can often be discerned, see Section 5.1. Inheritance patterns.
3.4 Genetic testing
Genetic testing requires knowledge about genetics, the disease in question, as 
well as legal and ethical considerations. It is important that the patient is the one 
who makes an informed decision about if a gene test should be performed [13]. 
It is also important to be aware of what the benefits and potential detriments of a 
genetic test are. The current ESC Heart failure guidelines from 2016 recommend 
that genetic testing should be performed in accordance with the ESC position state-
ment on genetic counseling and testing in cardiomyopathies from 2010 [1, 13]. Most 
genotypes cannot be distinguished from each other by evaluation of the phenotype. 
Due to this broad gene panels are required that incorporate most known definite 
and putative DCM genes. The ESC states that the main role of genetic testing is in 
patients with an already confirmed diagnosis of idiopathic DCM (where acquired 
causes has been ruled out) to enable genetic testing of first degree-relatives and 
possibly cascade screening, see Section 5.2. Family screening. They caution against 
the use of genetic testing to establish the diagnosis of a cardiomyopathy in border-
line cases except for in the setting of expert teams after detailed clinical and family 
assessment. In definite DCM most often, the exact gene affected do not change the 
clinical management of that individual patient. However, in some cases of DCM 
with red flags such as simultaneous conductions disorders indicative of a specific 
phenotype, genetic testing can be used to establish a specific genetic diagnosis. In 
patients with mutations in LMNA that causes DCM, genetic diagnosis might affect 
the clinical management. It should be noted that negative genetic tests do not rule 
out that the cardiomyopathy is familial or genetic. The interpretation of genetic 
tests is time consuming, complicated, and often not conclusive. When the ESC posi-
tion statement was written in 2010 genetic tests had been mainly used for research 
purposes and had recently become available for clinicians. Genetic tests have today 
become more affordable and available. The current trend is towards more genetic 
evaluations being conducted and it is our opinion that this trend should continue. 
More patients with DCM receiving a genetic diagnosis will over time improve 
knowledge of the different genotypes. In order to offer equal health care genetic 
testing must be conducted even outside the setting of tertiary centers.
4. Clinical management of dilated cardiomyopathy
4.1 Heart failure
Heart failure management should be in accordance with guidelines, such as 
those of the ESC, which are summarized below [1]. An angiotensin converting 
enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) is indicated in left 
ventricular systolic dysfunction. If symptomatic, i.e. New York Heart Association 
functional classification (NYHA-class) 2 or above, a beta-blocker should be added 
to treatment with the ACEi/ARB. In patients who remain symptomatic with systolic 
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ejection fraction ≤35% despite the highest tolerable evidence-based doses of ACEi 
or ARB as well as a beta-blocker, a mineral receptor antagonist is recommended 
with maximum tolerated evidence-based dose. If the patient is still symptomatic 
with systolic ejection fraction ≤35% it is recommended to initiate treatment with an 
angiotensin receptor neprilysin inhibitor that replaces the ACEi/ARB [1]. Further 
treatment modalities that should be considered include the addition of ivabradine 
in patients with sinus rhythm ≥70 beats per minute, or the implantation of a cardiac 
device to allow for cardiac resynchronization therapy in those with left bundle 
branch block and QRS ≥130 ms or without left bundle branch block but QRS 
≥150 ms. These mentioned treatment modalities have shown increased survival in 
randomized controlled trials [1]. Digoxin could be considered if symptoms remain, 
however reduced mortality has not been shown but rather reduced need for hospi-
talization. The small therapeutic window of digoxin should be kept in mind, most 
commonly digoxin is used for rate control in atrial fibrillation that is common in 
heart failure. Loop-diuretics such as furosemide should be considered in patients 
with heart failure to relieve symptoms and signs of congestion, but this has not been 
shown to reduce mortality. The dosage of diuretics should be kept as low as pos-
sible and cessation of treatment might often be possible. In end-stage heart failure, 
transplant might be considered or mechanical left ventricular assist devices that can 
be used as destination therapy, bridge-to-decision, or bridge to transplant [1].
Lately inhibition of sodium-glucose transporter protein 2 (SGLT2i) has proved 
an interesting treatment modality for heart failure with reduced ejection frac-
tion. In the EMPA-REG trial in 2015, the SGLT2i empagliflozin showed reduced 
cardiovascular mortality, reduction in all-cause mortality, and reduced need for 
hospitalization for heart failure in patients with type 2 diabetes mellitus [14]. In 
2019 the results of the DAPA-HF trial showed that the SGLT2i dapagliflozin reduced 
cardiovascular and all-cause mortality as well as risk of worsening heart failure in 
patients with heart failure with reduced ejection fraction even if they did not have 
diabetes mellitus [15].
4.2 Arrhythmia
There is an increased risk for both brady- and tachyarrhythmia in DCM, these 
arrhythmias can also be a contributing factor worsening heart failure. In symp-
tomatic sinus node disease or in high-degree atrioventricular (AV)-block without 
a reversible cause a pacemaker is indicated in order the relieve symptoms and/or 
increase survival [3]. Beta-blockers are often indicated for the treatment of symp-
tomatic heart failure but also have antiarrhythmic properties making it useful for 
both rhythm and rate control. With the exception of beta-blockers currently avail-
able antiarrhythmic drugs have not consistently been shown in randomized clinical 
trials to improve survival in the primary management of arrhythmia. Amiodarone 
have shown some positive results and is highly useful to control symptoms, to ter-
minate tachyarrhythmia and prevent recurrence [3]. In heart failure with reduced 
ejection fraction most other antiarrhythmic agents are contraindicated, this 
includes flecainide and dronedarone otherwise frequently used for rhythm control 
in atrial fibrillation [3].
4.3 Prevention of sudden cardiac death
An implantable cardioverter defibrillator (ICD) is an effective way to prevent 
sudden cardiac death in those at risk for developing ventricular tachycardia or ven-
tricular fibrillation [3]. An ICD offers both antitachycardia pacing, rapid ventricular 
pacing (preferably bursts), that can terminate ventricular tachycardia, as well as 
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cardioversion that effectively terminate ventricular tachycardia and ventricular fibril-
lation. In addition, an ICD also functions as a bradycardia pacemaker and in combi-
nation with a left-ventricular lead it can offer cardiac resynchronization therapy.
The ESC recommends a primary prophylactic ICD for patients with symptom-
atic heart failure (NYHA-class II-III), left ventricular systolic ejection fraction 
≤35% despite at least three months of optimal medical therapy and a life expec-
tancy of at least 1 year [3]. The recommendation is class I (is recommended) for 
both heart failure due to ischemic heart disease as well as nonischemic cardiomy-
opathy. The level of evidence is considered stronger for heart failure with ischemic 
etiology (level A) than for nonischemic etiology (level B) [3]. In the SCD-HeFT 
trial an ICD reduced all-cause mortality as well as sudden cardiac death in patients 
with reduced ejection fraction [16]. In the DEFINITE trial, with a study popula-
tion of patients with heart failure due to nonischemic etiology, sudden cardiac 
death was reduced by 80%, however reduction in all-cause mortality did not reach 
statistical significance (hazard ratio 0.65, p = 0.08) [17]. In 2016, the DANISH 
trial randomized participants with heart failure of nonischemic origin to either 
an ICD or otherwise optimal medical management (both groups were eligible for 
cardiac resynchronization therapy), after 5 years there was a significant reduc-
tion in sudden cardiac death (HR; 0.50, p = 0.005) [18]. For the whole group no 
significant reduction was seen in all-cause mortality (HR; 0.87, p = 0.28), however 
subgroup analysis of patients younger than 68 years showed a reduction all-cause 
mortality (hazard ratio 0.64; p = 0.01) [18]. This caused uncertainty about whether 
patients with heart failure of nonischemic etiology should receive ICDs on the same 
indications as those with ischemic etiology. Since then, a meta-analysis of six trials, 
that included DANISH, has showed that ICD on primary-prevention indication 
in patients with heart failure of nonischemic etiology reduced all-cause mortal-
ity (hazard ratio 0.76, p = 0.001) [19]. An analysis of the Swedish Heart Failure 
Registry revealed a 27% relative risk reduction in all-cause mortality after 1 year, 
this was consistent in both the subgroup with ischemic and with nonischemic 
etiology [20]. We have previously published a retrospective observational study of 
our ICD-cohort [21]. In our study 236 patients with primary prevention ICD due to 
heart failure of ischemic (61.9%) or nonischemic (38.1%) etiology were included, 
there was no difference in cumulative risk for appropriate therapy between the 
groups (Mantel-Cox p = 0.985) [21]. The guidelines of the ESC recommending 
implantation of a primary prevention ICD should therefore be followed in patients 
with heart failure with both ischemic etiology as well as nonischemic DCM [3].
5. Familial dilated cardiomyopathy
5.1 Inheritance patterns
Most genetic mutations that cause familial DCM have an autosomal dominant 
inheritance pattern with variable penetrance [22]. However, autosomal recessive, 
X-linked recessive and mitochondrial inheritance patterns have been described 
[22]. Sometimes a mutation is found that does not occur in any of the parents, this is 
called a de novo mutation.
5.1.1 Autosomal dominant
Autosomal inheritance is related to a mutation in an autosome, i.e. any chromo-
some that is not a sex chromosome. Dominant inheritance pattern implies that it is 
enough with only one mutant allele for the disease to be expressed. This means that 
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the effect of a mutation in a gene masks or overrides the effect of a normal variation 
of the same gene on the other copy of the same chromosome. Those who have only a 
mutation in one of their two gene copies are said to be heterozygous. Due to a com-
plex interplay with other genes and with the environment the disease is not always 
expressed, this is called varying penetrance. Men and women are equally as likely 
to inherit a mutated gene from a parent that carries it, regardless if it is the father or 
mother. If one parent carries one copy of the mutated gene, the offspring has a 50% 
risk of inheriting it. If both parents carry one copy of the gene, the offspring has a 
75% risk of inheriting at least one copy.
5.1.2 Autosomal recessive
Autosomal recessive inheritance is caused by mutation in a gene situated on an 
autosome but requires both the copy inherited from the father and the copy from 
the mother to be mutaded. For the mutation to cause the disease to be expressed 
the carrier needs to be homozygous for the mutation. This inheritance pattern 
requires both parents to carry at least one gene affected by the mutation. Men and 
women are equally as likely to inherit two affected gene copies from a certain pair 
of parents. If both parents carry one mutated gene, the offspring has a 25% risk of 
inheriting two mutated gene copies.
5.1.3 X-linked recessive
X-linked recessive inheritance pattern is caused by a mutation in a gene situated 
on the X chromosome. Since the X chromosome is a sex chromosome and females 
have two copies while males have only one copy, if the inheritance pattern is reces-
sive, males will be affected, while females need to inherit a mutated gene from 
both their father and mother in order to be affected. Since men never inherit their 
X-chromosome from their father, the mutated gene can never pass to a son from 
his father. Daughters have always inherited one of their X-chromosomes from their 
father, thus an affected father will always have passed the mutated gene on to his 
daughters. This daughter will only be a carrier and not affected by the disease, unless 
she also has inherited the mutated gene from her mother. It is therefore common for 
X-linked recessive diseases to skip generations of daughters. A female that carry one 
mutated gene copy have a 50% risk of passing this on to both their sons and daughters.
5.1.4 Mitochondrial inheritance
In humans, mitochondria, and also mutations affecting mitochondrial DNA, is 
inherited from the mother. Both males and female can be affected by mitochondrial 
disease but only females can pass on the mutation to their offspring.
5.2 Family screening
5.2.1 Family screening in case of a known mutation
In many European countries including Sweden, the physician has no legal right 
to contact or inform first-degree relatives about the results of a genetic test. Instead 
the patient must be equipped with sufficient knowledge, both verbally and in writ-
ten form to inform relatives about the genetic aspect of the disease, although usually 
there is no legal obligation for the patient to do this.
If the proband, the first identified individual with DCM in a family, has a 
known disease-causing mutation it is possible to screen all first-degree relatives 
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for this single mutation [13]. If the inheritance pattern is autosomal dominant, 
children each have 50% risk of carrying the mutation. A simple genetic test could 
with certainty confirm or reject that an individual carries the mutation, this has 
large implications. If the individual is not a carrier of the mutated gene, no further 
follow-up is required, no cascade screening is needed of this individual’s children, 
and the individual have a better chance of living a normal life.
If instead the gene test confirms that an individual carries the mutated gene, 
so called cascade screening should be considered of this individual’s first-degree 
relatives. Carrying a known disease-causing mutation implies that cardiologic evalu-
ation should be conducted consisting of at least 12-lead ECG and echocardiography. 
If this evaluation results in a diagnosis of DCM life-long follow-up is required. If this 
cardiologic evaluation is inconclusive or finds no signs of DCM continued follow-up 
is still required. The penetrance of familial DCM is most often age-dependent, age at 
diagnosis of DCM is most often seen during or after puberty up until 60 years of age 
[13]. Therefore, renewed assessment with at least ECG and echocardiography should 
be conducted every year between the ages of 10 and 20 and then every 1–3 years.
5.2.2 Family screening in case of no known mutation
In idiopathic DCM, in a setting where genetic testing is not available, negative, or 
inconclusive, familial DCM can still not be ruled out. All first-degree relatives of the 
proband should undergo cardiologic evaluation with at least 12-lead ECG and echo-
cardiography [13]. If they are diagnosed with DCM life-long follow-up is required and 
all their first-degree relatives should undergo cardiologic evaluation as well. If instead 
the cardiologic evaluation is negative for DCM, the relative should be followed-up 
with repeat cardiologic evaluations; every 1–3 years for those younger than 10 years of 
age, every 1–2 years between the age of 10 and 20, and every 2–5 years from 20 years 
of age up until 50–60 years of age. The reason for this continued evaluation during life 
is the age-dependent penetrance. For those affected, penetrance is almost complete at 
60 years of age, therefore repeated evaluation is not necessary after this [13].
6. Causative gene mutations
Many genes have been linked to DCM, some with a definite and some with a 
putative link. For definite DCM genes see Table 1, adapted from McNally et al. [22]. 
It is often difficult to determine if a mutation in a gene is causative of cardiomy-
opathy, sometimes mutations are determined to be so called variants of unknown 
significance. Most genes implicated in the pathogenesis of DCM are highly con-
served with few de novo mutations occurring, making new mutations, found in a 
known DCM gene that alters the encoded protein, likely to be pathogenic.
Mutations that have been linked to DCM affect genes related to diverse cell 
structures such as; ion channels, dystrophin complexes, sarcoplasmic reticulum, 
nuclear lamina, desmosomes, mitochondria, cytoskeleton, z-disc, and sarcomeres. 
For an image visualizing different cellular structures related to definite DCM genes 
see Figure 3.
6.1 Genes associated with sudden cardiac death
The general consensus is that risk of arrhythmia in DCM scales with the degree of 
left ventricular systolic dysfunction. Most genotypes cannot be distinguished from 
each other by evaluation of the phenotype. Due to this broad gene panels are required. 
However, some genotypes have been shown to be prone to arrhythmia and in some 
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Gene Protein Frequency and overlapping phenotypes
Sarcomere Force generation/transmission
MYH7 Beta-myosin heavy chain 3–4% of DCM; HCM, LVNC
TPM1 Alpha-tropomyosin 1–2% of DCM; HCM, LVNC
ACTC1 Alpha cardiac actin HCM, LVNC
TNNT2 Cardiac troponin T 3% of DCM; HCM, LVNC
TNNC1 Cardiac troponin C HCM, LVNC
TNNI3 Cardiac troponin 1 HCM
TTN Titin 12–25% of DCM; HCM, tibial muscle 
dystrophy
TNNI3K Troponin 1 interacting kinase Conduction defect, atrial fibrillation
Z-disc Mechanosensing/mechanosignaling
ACTN2 Alpha-actinin 2 LVNC
BAG3 BCL2 Associated Athanogene 3 Myofibrillar myopathy
CRYAB Alpha-B-crystallin Protein aggregation myopathy
TCAP Titin-cap/telethonin LGMD2G
CSRP3 Muscle LIM protein HCM
ANKRD1 Cardiac ankyrin repeat protein Congenital heart disease
LDB3 Cipher/ZASP LVNC
NEBL Nebulette LVNC, HCM
Dystrophin complex Sarcolemma, structural integrity





DES Desmin <1% of DCM; desminopathies, myofibrillar 
myopathy
VCL Metavinculin 1% of DCM
FLNC Filamin C 1% of DCM; myofibrillar myopathy, HCM, 
RCM
Desmosomes Cell–cell adhesion/mechanotransmission/mechanosignaling
DSP Desmoplakin 2% of DCM; ARVC
Sarcoplasmic reticulum and cytoplasm Ca homeostasis, contractility modulation, signaling
PLN Phospholamban ARVC, HCM
Nuclear envelope Nuclear structural integrity, mechanotransduction, mechanosignaling
LMNA Lamin A/C 4–8% of DCM; multiple phenotypes, 
LGMD1B, EDMD, progeria
EMD Emerin EDMD
Nucleus Transcription cofactors, gene expression
RBM20 RNA-binding protein 20 2% of DCM; RNA-binding protein of 
spliceosome of TTN and other proteins
Ion channels Transportation of ions
SCN5A Type V voltage-gated cardiac Na 
channel




cases sudden cardiac death. Some genes are very rare, or only putative and not defini-
tively linked to DCM. Out of the genes that regularly are found to cause DCM, LMNA 
and SCN5A stand out for their propensity to cause arrhythmia. Mutations in both of 
these genes can cause a phenotype with atrial fibrillation, conduction system disease 
or ventricular tachyarrhythmia as the presenting symptom [22]. Guidelines from the 
ESC give specific indications for the implantation of an ICD in patients with DCM 
and LMNA mutation, these are described below [3]. For SCN5A no specific guidelines 
are given [3]. However, it is reasonable to adapt clinical management for patients with 
mutation in this gene to account for the known risk for arrhythmia. This also holds 
true for patients with other or unknown mutations, but with a family history indica-
tive of a high risk of arrhythmia and sudden cardiac death. Such adaptations might 
include more frequent ambulatory ECG-monitoring or the use of insertable cardiac 
monitors to screen for potentially life-threatening arrhythmias.
6.1.1 LMNA
LMNA, the gene encoding the proteins lamin A and C, is one of the most studied 
DCM genes. Lamin A/C form part of the nuclear lamina and have been implicated 
in several cellular processes, including regulation of gene expression [22]. DCM 
Gene Protein Frequency and overlapping phenotypes
ABCC9 Component of ATP-sensitive 
potassium channel
Atrial fibrillation, osteochondrodysplasia
KCNQ1 Potassium channel Atrial fibrillation, LQTS1, short QT1, Jervell 
and Lange-Nielsen syndrome
Mitochondria Supply and/or regulation of energy metabolism
DNAJC19 HSP40 homolog, C19 3-methylglutaconic aciduria type V
TAZ/G4.5 Tafazzin LVNC, Barth syndrome, endocardial 
fibroelastosis 2
ARVC: arrhythmogenic right ventricular cardiomyopathy; DCM: dilated cardiomyopathy; EDMD: Emery Dreifuss 
muscular dystrophy; HCM: hypertrophic cardiomyopathy; LGMD: limb-girdle muscular dystrophy; LVNC: left 
ventricular non-compaction cardiomyopathy; LQTS: long QT-syndrome; RCM: restrictive cardiomyopathy. Adapted 
from McNally et al. [22].
Table 1. 
Definite dilated cardiomyopathy genes.
Figure 3. 
Cross section of two cardiomyocytes that connect to each other with desmosomes at the intercalated disc. Definite 
DCM genes and important cellular structures pertaining to them are named. Image by Todd Cooper.
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associated with mutation in LMNA tend to have age-dependent penetrance but 
with disease onset early in life, often dysrhythmias mainly conduction disturbances 
and atrial fibrillation precede the development of heart failure. The risk for sudden 
cardiac death is also increased, even with only moderately reduced left ventricular 
ejection fraction [3]. Guidelines of the ESC state that an ICD should be considered 
(class of recommendation IIa) for patients with DCM and a confirmed disease-
causing mutation in LMNA if any of the following clinical risk factors are present; 
non-sustained ventricular tachycardia, left ventricular ejection fraction ≤45%, male 
sex, or a non-missense mutation (insertion, deletion, truncation or mutation affect-
ing splicing) [3]. This recommendation is based upon the results of a cohort study 
of 269 patients with LMNA-mutation and a median follow-up time of 43 months, 
48 patients (18%) reached the composite endpoint of sudden cardiac death, appro-
priate ICD therapy, or aborted cardiac death [23]. In a review of published cohorts 
of patients with LMNA-associated cardiomyopathy, in total 299 patients, some sort 
of dysrhythmia was reported in 92% after the age of 30 years [24]. Dysrhythmias 
included sinus bradycardia, first-degree AV-block, and atrial or ventricular tachyar-
rhythmias [24]. Notably, almost half died from sudden cardiac death [24]. This 
high proportion of sudden cardiac death was also noted in those patients who had 
a pacemaker implanted, which implies that the mode of death in LMNA-associated 
cardiomyopathy may be caused by ventricular tachyarrhythmias [24].
6.1.2 SCN5A
Mutations in SCN5A, the gene that encodes the sodium voltage-gated channel 
alpha subunit 5 involved in the main cardiac sodium channel, has been linked to 
several diseases including Brugada syndrome, long QT-syndrome as well as DCM 
and ARVC [25]. Different kinds of mutations in SCN5A have been linked to DCM 
and the mechanism is still uncertain. Interestingly, the phenotype varies in families 
with the same genotype, indicating that environmental or other confounding 
factors are at play [25]. Mutations in SCN5A have also been linked to progressive 
conduction disorder and familial atrial fibrillation. Given this, it is not surprising 
that DCM due to SCN5A often presents with increased risk of arrhythmia [22].
7. Future perspectives
Currently, familial DCM is likely frequently underdiagnosed, and often genetic 
testing is not conducted. Increased awareness and availability of genetic evalua-
tion might provide more knowledge and gene-specific therapies and management 
might become available. Increased identification of affected families will mean that 
more at-risk individuals will come into contact with health care providers prior to 
developing the phenotype. This means that future studies should focus on therapies 
aimed to prevent the development of DCM in these individuals. Further research 
into the different genotypes and their burden of arrhythmia is also warranted in 
order to improve risk stratification for sudden cardiac death. This includes the utili-
zation of implantable cardiac monitors in those patients who have certain high-risk 
genotypes but have been judged not to fulfill criteria for the implantation of an ICD.
8. Conclusion
Reduced left ventricular systolic ejection fraction is the most common indication 
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genes have been linked to a propensity for arrhythmia, chief among them LMNA 
and SCN5A. A mutation in LMNA together with other clinical risk factors could 
warrant implantation of an ICD.
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